Available for licensing and co-development are antibody-drug conjugates (ADC) that incorporate one of two novel human CD56 antibodies, known as m900 and m906, in combination with a known cytotoxic drug, pyrrolobenzodiazepine (PBD).
Researchers at the National Cancer Institute (NCI) have developed a combination of immunoadjuvants and immune checkpoint inhibitors to stimulate an immune response against cancer. The combination therapy has been tested in xenograft models and shown successful for both treatment of an existing tumor and resistance to re-challenge. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for mesothelin targeting Recombinant Immunotoxins (RITs). These RITs have been engineered by site specific modification with polyethylene glycol (PEG) to have an increased serum half-life, while maintaining high cytotoxicity and have greatly improved anti-tumor activity.
Novel thalidomide analogs and their use as immunomodulatory agents are disclosed in this invention by scientists at the National Institute on Aging (NIA). These therapeutic compounds could reduce chronic systemic and central nervous system inflammation. The NIA seeks licensing or co-development partners to commercialize this technology.
Researchers at the National Institute on Aging (NIA) have developed a novel strategy for rendering weakly or non-immunogenic, shared (between self and tumor) antigens immunogenic, or able to produce an immune response. Further, they have created therapeutic polypeptides comprising tumor-associated embryonic antigens and chemoattractant ligands. Cancers targeted by these developments include breast, renal, lung, ovarian, and hematological cancers.
Researchers at the National Cancer Institute (NCI) developed a treatment regimens for cancer and HIV using heterodimeric IL-15 (hetIL-15). The regimens allow access to B cell follicles, germinal centers, and tumor sites that are difficult for drug entry. A combination therapy for HIV infection is also described using hetIL-15 and a conserved element vaccine. Researchers seek licensing and/or co-development research collaborations for development and commercialization of treatment regimens for HIV infection.
Researchers at the NCI have developed a method of improving the immune response in cancer immunotherapy by exploiting in the role of the Linker Adapted for T-Cell Signaling (LAT) molecule. The LAT molecular can enhance signaling through TCRs, thus, improving a patient’s own immune response to cancer or infectious diseases.
The National Cancer Institute (NCI) seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate). Acetalax is a previously FDA approved drug that has been used as a topical laxative but is being repurposed here as an onco-therapy because of its cytotoxic effects on a number of TNBC and other cancer cell lines.
The National Cancer Institute's Laboratory of Experimental Immunology, Cancer Inflammation Program, seeks parties interested in collaborative research to co-develop, evaluate, or commercialize the use of certain cucurbatacins or withanolides in combination with pro-apoptotic agonists of TRAIL death receptors for cancer therapy.
Researchers at the National Cancer Institute (NCI) have developed a technology that provides methods of performing adoptive cell transfer (ACT), an immunotherapeutic approach for cancer treatment, by administering a heterodimeric Interleukin 15/Interleukin 15 receptor alpha (IL-15/IL-15Rα) complex (hetlL-15) in the absence of lymphodepletion, thereby eliminating any lymphodepletion-associated detrimental side effects.
Increased cyclin-dependent kinase 5 (CDK5) activity has recently emerged as a contributor to cancer progression. Researchers at the National Cancer Institute (NCI) and at the National Institute of Neurological Disorders and Stroke (NINDS) have shown that TP5, a small peptide inhibitor of CDK5 modified to facilitate passage through the blood brain barrier (BBB), has potential therapeutic benefit in glioblastoma (GBM) and colorectal carcinoma (CRC). NCI is seeking parties interested in co-developing and/or licensing TP5 for its use in the treatment of cancers with aberrant CDK5 expression as a mono-therapy or in an adjuvant setting with current standard-of-care.
The present invention describes novel virus-like particles (VLPs) that are capable of binding to and replicating within a target mammalian cell, including human cells. The claimed VLPs are safer than viral delivery because they are incapable of re-infecting target cells. The National Cancer Institute's Protein Expression Laboratory seeks parties interested in licensing the novel delivery of RNA to mammalian cells using virus-like particles.